3月20日 - ** 药物开发商Optinose（OPTN.O）股价上涨60%，至9.60美元
**OPTN称 ， (link) 私人控股的Paratek Pharmaceuticals 将以最高3.3亿美元的价格收购co及其 鼻腔喷雾剂Xhance
** Xhance用于治疗一种 称为慢性鼻窦炎的 长期鼻窦和鼻腔炎症
**交易对 每股的潜在估值最高可达14美元，包括每股9美元的前期估值，较股票最后收盘价溢价50
** 截至最新收盘，OPTN在过去12个月下跌了76.7%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.